Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expression of CXCL5 in Urinary Bladder Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05139134
Recruitment Status : Recruiting
First Posted : December 1, 2021
Last Update Posted : December 1, 2021
Sponsor:
Information provided by (Responsible Party):
Nagwa Abd El-Sadek Ahmed, Sohag University

Brief Summary:
Bladder carcinoma is the 9th most prevalent cancer worldwide and the 13th most common cause of cancer-related deaths. Approximately three quarters of all cases are diagnosed in men. Lack of understanding of mechanisms that govern bladder carcinoma metastasis and recurrence is a major reason for its high mortality rates. CXCL5 is a small (8-14 kDa) protein that is a member of the CXC chemokine family. It is an inflammatory and angiogenic chemokine that binds to its cell-surface receptor CXCR2 to execute its roles in angiogenesis, immune response, tumor progression and invasion by activating the PI3K/AKT pathway-induced up regulation of matrix metalloproteinase. Numerous reports have indicated that CXCL5 plays vital roles in cancer progression in various neoplasms; abnormal expression of CXCL5 has been identified in many tumors. Increased expression of CXCL5 is associated with advanced tumor stages, local invasion, metastatic potential and cancer-related inflammation, which is involved in many aspects of malignancy in cancer biology. Recent studies have revealed that CXCL5 could serve as a potential prognostic biomarker for patients with bladder carcinoma.

Condition or disease
Urinary Bladder Urothelial Carcinoma

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
Estimated Study Start Date : January 1, 2022
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : November 1, 2022

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. evaluate the expression of CXCL5 in non-invasive and invasive urothelial carcinoma of the urinary bladder and to correlate its expression to different studied histopathological parameters to evaluate its potential prognostic value [ Time Frame: 1 month ]
    Immunohistochemical study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Fifty specimens of primary invasive and non-invasive urothelial bladder carcinomas obtained from patients who underwent cystoscopic resection and/or radical cystectomy in Urology Department of Sohag Faculty of Medicine, according to local Ethical Committee regulations, to be examined in the Pathology Laboratory of the same Faculty.
Criteria

Inclusion Criteria:Patients with primary invasive and non-invasive urinary bladder urothelial carcinomas.

-

Exclusion Criteria:

  • - Patients received pre-operative chemotherapy or radiotherapy.
  • Patients with insufficient clinical data.
  • Specimens with extensive necrosis
  • Tiny specimens which are insufficient for accurate diagnosis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05139134


Contacts
Layout table for location contacts
Contact: Nagwa Ahmed, Lecturer 01017415996 nagwa.sadek@med.sohag.edu.eg

Locations
Layout table for location information
Egypt
Faculty of Medicine, Sohag University Recruiting
Sohag, Egypt
Contact: Ahmed Roshdi, Assist. prof         
Sponsors and Collaborators
Sohag University
Investigators
Layout table for investigator information
Principal Investigator: Nagwa Ahmed, Lecturer Sohag University
Layout table for additonal information
Responsible Party: Nagwa Abd El-Sadek Ahmed, Lecturer at Pathology Department, Faculty of Medicine, Sohag University, Sohag University
ClinicalTrials.gov Identifier: NCT05139134    
Other Study ID Numbers: Soh-Med-21-10-43
First Posted: December 1, 2021    Key Record Dates
Last Update Posted: December 1, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nagwa Abd El-Sadek Ahmed, Sohag University:
CXCL5
Urothelial Carcinoma
Prognostic value
Cancer progression
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms